Association between Melanocytic Nevi and Risk of Breast Diseases: The French E3N Prospective Cohort

PLoS Medicine

Volumn 11, Issue 6, 2014, Pages 1-12

  Kvaskoff, Marina ^a,b,c,d,e   Bijon, Anne ^a,b,c   Mesrine, Sylvie ^a,b,c   Vilier, Alice ^a,b,c   Baglietto, Laura ^f,g   Fournier, Agnès ^a,b,c   Clavel Chapelon, Françoise ^a,b,c   Dossus, Laure ^a,b,c   Boutron Ruault, Marie Christine ^a,b,c  

^a CENTRE FOR RESEARCH IN EPIDEMIOLOGY AND POPULATION HEALTH   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^f CANCER EPIDEMIOLOGY CENTRE   (Australia)

^g UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; ARTICLE; BODY MASS; BREAST CANCER; BREAST NEOPLASMS; CANCER RISK; COMPLICATION; ETIOLOGY; FAMILY; FEMALE; FOLLOW UP; FRANCE; GENETIC ASSOCIATION; HAZARD RATIO; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; MELANOCYTE; MELANOCYTIC NEVUS; MIDDLE AGED; NEVUS; PHONETICS; PREMENOPAUSE; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; QUESTIONNAIRE; RISK FACTOR; SENSITIVITY ANALYSIS; SKIN TUMOR; STATISTICAL MODEL; ULTRAVIOLET RADIATION;

ADULT; BREAST NEOPLASMS; COMPLICATIONS; ETIOLOGY; FAMILY; FEMALE; FRANCE; HUMANS; LOGISTIC MODELS; MELANOCYTES; MIDDLE AGED; NEVUS; PREMENOPAUSE; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK FACTORS; SKIN NEOPLASMS;

EID: 84902454657     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.1001660     Document Type: Article

References (66)

1. Green A, Swerdlow AJ, (1989) Epidemiology of melanocytic nevi. Epidemiol Rev 11: 204-221.
2. McGregor B, Pfitzner J, Zhu G, Grace M, Eldridge A, et al. (1999) Genetic and environmental contributions to size, color, shape, and other characteristics of melanocytic naevi in a sample of adolescent twins. Genet Epidemiol 16: 40-53.
3. Wachsmuth RC, Gaut RM, Barrett JH, Saunders CL, Randerson-Moor JA, et al. (2001) Heritability and gene-environment interactions for melanocytic nevus density examined in a U.K. adolescent twin study. J Invest Dermatol 117: 348-352.
4. Wachsmuth RC, Turner F, Barrett JH, Gaut R, Randerson-Moor JA, et al. (2005) The effect of sun exposure in determining nevus density in UK adolescent twins. J Invest Dermatol 124: 56-62.
5. Falchi M, Bataille V, Hayward NK, Duffy DL, Bishop JA, et al. (2009) Genome-wide association study identifies variants at 9p21 and 22q13 associated with development of cutaneous nevi. Nat Genet 41: 915-919.
6. Zhu G, Montgomery GW, James MR, Trent JM, Hayward NK, et al. (2007) A genome-wide scan for naevus count: linkage to CDKN2A and to other chromosome regions. Eur J Hum Genet 15: 94-102.
7. Autier P, Boniol M, Severi G, Giles G, Cattaruzza MS, et al. (2001) The body site distribution of melanocytic naevi in 6-7 year old European children. Melanoma Res 11: 123-131.
8. Dodd AT, Morelli J, Mokrohisky ST, Asdigian N, Byers TE, et al. (2007) Melanocytic nevi and sun exposure in a cohort of Colorado children: anatomic distribution and site-specific sunburn. Cancer Epidemiol Biomarkers Prev 16: 2136-2143.
9. Harrison SL, Buettner PG, MacLennan R, (1999) Body-site distribution of melanocytic nevi in young Australian children. Arch Dermatol 135: 47-52.
10. Whiteman DC, Brown RM, Purdie DM, Hughes MC, (2005) Melanocytic nevi in very young children: the role of phenotype, sun exposure, and sun protection. J Am Acad Dermatol 52: 40-47.
11. Dennis LK, White E, Lee JA, Kristal A, McKnight B, et al. (1996) Constitutional factors and sun exposure in relation to nevi: a population-based cross-sectional study. Am J Epidemiol 143: 248-256.
12. Kelly JW, Rivers JK, MacLennan R, Harrison S, Lewis AE, et al. (1994) Sunlight: a major factor associated with the development of melanocytic nevi in Australian schoolchildren. J Am Acad Dermatol 30: 40-48.
13. Valiukeviciene S, Miseviciene I, Gollnick H, (2005) The prevalence of common acquired melanocytic nevi and the relationship with skin type characteristics and sun exposure among children in Lithuania. Arch Dermatol 141: 579-586.
14. Dennis LK, White E, McKnight B, Kristal A, Lee JA, et al. (1996) Nevi and migration within the United States and Canada: a population-based cross-sectional study. Cancer Causes Control 7: 464-473.
15. Fritschi L, McHenry P, Green A, Mackie R, Green L, et al. (1994) Naevi in schoolchildren in Scotland and Australia. Br J Dermatol 130: 599-603.
16. Nguyen TD, Siskind V, Green L, Frost C, Green A, (1997) Ultraviolet radiation, melanocytic naevi and their dose-response relationship. Br J Dermatol 137: 91-95.
17. Richard MA, Grob JJ, Gouvernet J, Culat J, Normand P, et al. (1994) [Role of sun exposure on benign melanocytic nevi. A first study in populations controlled for age, sex and phenotype.]. Ann Dermatol Venereol 121: 639-644.
18. Rodvall Y, Wahlgren CF, Ullen H, Wiklund K, (2007) Common melanocytic nevi in 7-year-old schoolchildren residing at different latitudes in Sweden. Cancer Epidemiol Biomarkers Prev 16: 122-127.
19. Driscoll MS, Grant-Kels JM, (2007) Hormones, nevi, and melanoma: an approach to the patient. J Am Acad Dermatol 57: 919-931.
20. Rubegni P, Sbano P, Burroni M, Cevenini G, Bocchi C, et al. (2007) Melanocytic skin lesions and pregnancy: digital dermoscopy analysis. Skin Res Technol 13: 143-147.
21. Slominski A, Tobin DJ, Shibahara S, Wortsman J, (2004) Melanin pigmentation in mammalian skin and its hormonal regulation. Physiol Rev 84: 1155-1228.
22. Gandini S, Sera F, Cattaruzza MS, Pasquini P, Abeni D, et al. (2005) Meta-analysis of risk factors for cutaneous melanoma: I. Common and atypical naevi. Eur J Cancer 41: 28-44.
23. Mellemkjaer L, Christensen J, Frederiksen K, Pukkala E, Weiderpass E, et al. (2011) Risk of primary non-breast cancer after female breast cancer by age at diagnosis. Cancer Epidemiol Biomarkers Prev 20: 1784-1792.
24. Yang GB, Barnholtz-Sloan JS, Chen Y, Bordeaux JS, (2011) Risk and survival of cutaneous melanoma diagnosed subsequent to a previous cancer. Arch Dermatol 147: 1395-1402.
25. Mitchell PJ, Perez-Nadales E, Malcolm DS, Lloyd AC, (2003) Dissecting the contribution of p16(INK4A) and the Rb family to the Ras transformed phenotype. Mol Cell Biol 23: 2530-2542.
26. Kvaskoff M, Mesrine S, Clavel-Chapelon F, Boutron-Ruault MC, (2009) Endometriosis risk in relation to naevi, freckles and skin sensitivity to sun exposure: the French E3N cohort. Int J Epidemiol 38: 1143-1153.
27. Kvaskoff M, Bijon A, Mesrine S, Clavel-Chapelon F, Boutron-Ruault MC, (2010) Pigmentary traits and risk of endometriosis. Hum Reprod 25: 3157-3158.
28. Redondo P, Idoate M, De Felipe I, (1998) Nevi related to thyroid diseases. Arch Intern Med 158: 1577.
29. Clavel-Chapelon F, van Liere MJ, Giubout C, Niravong MY, Goulard H, et al. (1997) E3N, a French cohort study on cancer risk factors. E3N Group. Etude Epidemiologique aupres de femmes de l'Education Nationale. Eur J Cancer Prev 6: 473-478.
30. Verdebout J, (2004) A European satellite-derived UV climatology available for impact studies. Radiat Prot Dosimetry 111: 407-411.
31. Resnik S, (1967) Melasma induced by oral contraceptive drugs. JAMA 199: 601-605.
32. Borges V, Puig S, Malvehy J, (2011) [Melanocytic nevi, melanoma, and pregnancy.]. Actas Dermosifiliogr 102: 650-657.
33. Bradford PT, Freedman DM, Goldstein AM, Tucker MA, (2010) Increased risk of second primary cancers after a diagnosis of melanoma. Arch Dermatol 146: 265-272.
34. Goggins W, Gao W, Tsao H, (2004) Association between female breast cancer and cutaneous melanoma. Int J Cancer 111: 792-794.
35. Soerjomataram I, Louwman WJ, Lemmens VE, Coebergh JW, de Vries E, (2008) Are patients with skin cancer at lower risk of developing colorectal or breast cancer? Am J Epidemiol 167: 1421-1429.
36. Spanogle JP, Clarke CA, Aroner S, Swetter SM, (2010) Risk of second primary malignancies following cutaneous melanoma diagnosis: a population-based study. J Am Acad Dermatol 62: 757-767.
37. Wassberg C, Thorn M, Yuen J, Hakulinen T, Ringborg U, (1999) Cancer risk in patients with earlier diagnosis of cutaneous melanoma in situ. Int J Cancer 83: 314-317.
38. Ewertz M, Mouridsen HT, (1985) Second cancer following cancer of the female breast in Denmark, 1943-80. Natl Cancer Inst Monogr 68: 325-329.
39. Galper S, Gelman R, Recht A, Silver B, Kohli A, et al. (2002) Second nonbreast malignancies after conservative surgery and radiation therapy for early-stage breast cancer. Int J Radiat Oncol Biol Phys 52: 406-414.
40. Harvey EB, Brinton LA, (1985) Second cancer following cancer of the breast in Connecticut, 1935-82. Natl Cancer Inst Monogr 68: 99-112.
41. Kirova YM, De Rycke Y, Gambotti L, Pierga JY, Asselain B, et al. (2008) Second malignancies after breast cancer: the impact of different treatment modalities. Br J Cancer 98: 870-874.
42. Mellemkjaer L, Friis S, Olsen JH, Scelo G, Hemminki K, et al. (2006) Risk of second cancer among women with breast cancer. Int J Cancer 118: 2285-2292.
43. Prochazka M, Hall P, Granath F, Czene K, (2006) Family history of breast cancer and young age at diagnosis of breast cancer increase risk of second primary malignancies in women: a population-based cohort study. Br J Cancer 95: 1291-1295.
44. Rubino C, de Vathaire F, Diallo I, Shamsaldin A, Le MG, (2000) Increased risk of second cancers following breast cancer: role of the initial treatment. Breast Cancer Res Treat 61: 183-195.
45. Schaapveld M, Visser O, Louwman MJ, de Vries EG, Willemse PH, et al. (2008) Risk of new primary nonbreast cancers after breast cancer treatment: a Dutch population-based study. J Clin Oncol 26: 1239-1246.
46. Soerjomataram I, Louwman WJ, de Vries E, Lemmens VE, Klokman WJ, et al. (2005) Primary malignancy after primary female breast cancer in the south of the Netherlands, 1972-2001. Breast Cancer Res Treat 93: 91-95.
47. Volk N, Pompe-Kirn V, (1997) Second primary cancers in breast cancer patients in Slovenia. Cancer Causes Control 8: 764-770.
48. Yu GP, Schantz SP, Neugut AI, Zhang ZF, (2006) Incidences and trends of second cancers in female breast cancer patients: a fixed inception cohort-based analysis (United States). Cancer Causes Control 17: 411-420.
49. Borg A, Sandberg T, Nilsson K, Johannsson O, Klinker M, et al. (2000) High frequency of multiple melanomas and breast and pancreas carcinomas in CDKN2A mutation-positive melanoma families. J Natl Cancer Inst 92: 1260-1266.
50. de Snoo FA, Hayward NK, (2005) Cutaneous melanoma susceptibility and progression genes. Cancer Lett 230: 153-186.
51. Bishop DT, Demenais F, Iles MM, Harland M, Taylor JC, et al. (2009) Genome-wide association study identifies three loci associated with melanoma risk. Nat Genet 41: 920-925.
52. Turnbull C, Ahmed S, Morrison J, Pernet D, Renwick A, et al. (2010) Genome-wide association study identifies five new breast cancer susceptibility loci. Nat Genet 42: 504-507.
53. Nickels S, Truong T, Hein R, Stevens K, Buck K, et al. (2013) Evidence of gene-environment interactions between common breast cancer susceptibility loci and established environmental risk factors. PLoS Genet 9: e1003284.
54. Agarwal P, Lutful Kabir FM, DeInnocentes P, Bird RC (2012) Tumor suppressor gene p16/INK4A/CDKN2A and its role in cell cycle exit, differentiation, and determination of cell fate. In: Cheng Y, editor. Tumor suppressor genes. Rijeka (Croatia): InTech.
55. Doisneau-Sixou SF, Sergio CM, Carroll JS, Hui R, Musgrove EA, et al. (2003) Estrogen and antiestrogen regulation of cell cycle progression in breast cancer cells. Endocr Relat Cancer 10: 179-186.
56. Liu T, Niu Y, Feng Y, Niu R, Yu Y, et al. (2008) Methylation of CpG islands of p16(INK4a) and cyclinD1 overexpression associated with progression of intraductal proliferative lesions of the breast. Hum Pathol 39: 1637-1646.
57. Debniak T, Gorski B, Huzarski T, Byrski T, Cybulski C, et al. (2005) A common variant of CDKN2A (p16) predisposes to breast cancer. J Med Genet 42: 763-765.
58. Baxter AJ, Hughes MC, Kvaskoff M, Siskind V, Shekar S, et al. (2008) The Queensland Study of Melanoma: environmental and genetic associations (Q-MEGA); study design, baseline characteristics, and repeatability of phenotype and sun exposure measures. Twin Res Hum Genet 11: 183-196.
59. Glanz K, Schoenfeld E, Weinstock MA, Layi G, Kidd J, et al. (2003) Development and reliability of a brief skin cancer risk assessment tool. Cancer Detect Prev 27: 311-315.
60. Westerdahl J, Anderson H, Olsson H, Ingvar C, (1996) Reproducibility of a self-administered questionnaire for assessment of melanoma risk. Int J Epidemiol 25: 245-251.
61. Clavel-Chapelon F, Dormoy-Mortier N, (1998) A validation study on status and age of natural menopause reported in the E3N cohort. Maturitas 29: 99-103.
62. Racine A, Bijon A, Fournier A, Mesrine S, Clavel-Chapelon F, et al. (2013) Menopausal hormone therapy and risk of cholecystectomy: a prospective study based on the French E3N cohort. CMAJ 185: 555-561.
63. Tehard B, van Liere MJ, Com Nougue C, Clavel-Chapelon F, (2002) Anthropometric measurements and body silhouette of women: validity and perception. J Am Diet Assoc 102: 1779-1784.
64. Kvaskoff M, Mesrine S, Fournier A, Boutron-Ruault MC, Clavel-Chapelon F, (2007) Personal history of endometriosis and risk of cutaneous melanoma in a large prospective cohort of French women. Arch Intern Med 167: 2061-2065.
65. Rothman KJ, (1990) No adjustments are needed for multiple comparisons. Epidemiology 1: 43-46.
66. Engel P, Fagherazzi G, Boutten A, Dupre T, Mesrine S, et al. (2010) Serum 25(OH) vitamin D and risk of breast cancer: a nested case-control study from the French E3N cohort. Cancer Epidemiol Biomarkers Prev 19: 2341-2350.